case_images: PMC5439250_01
case_images: Generalized cutaneous erythematous maculae with distinct edges.
case_images: CRIID2017-1489210.001.jpg
case_images: PMC5439250_01_CRIID2017-1489210.001.jpg
case_images: fig1
case_images: He had facial seborrheic eczema, generalized cutaneous erythematous maculae with distinct edges including palms and soles (Figure 1), a small nontender ulcer in the inferior lip, and a smooth nontender mild hepatomegaly.
case_images: Macular optic computed tomography of right eye, during active disease (a). Small vitreous inflammatory agglomerates and inflammatory deposits in neurossensorial retina; diffuse macular thickening. After resolution (b).
case_images: CRIID2017-1489210.002.jpg
case_images: PMC5439250_01_CRIID2017-1489210.002.jpg
case_images: fig2
case_images: He had a central scotoma in the right eye, with initially preserved peripheral vision that rapidly deteriorated; fundoscopy was highly suggestive of panuveitis, with fine keratic granulomatous precipitates, aqueous cells, flare grade 1, and choroidal and subretinal infiltration in the posterior pole (Figure 2(a)). During follow-up hormone replacement therapies were gradually tapered along with neurological and ocular improvement until complete resolution (Figure 2(b)).
case_images: MRI of sella turcica at admission (August 2014): heterogeneous enlargement with peripheral contrast enhancement.
case_images: CRIID2017-1489210.003.jpg
case_images: PMC5439250_01_CRIID2017-1489210.003.jpg
case_images: fig3
case_images: MRI of the sella turcica showed pituitary heterogeneous enlargement with peripheral contrast enhancement, with no pituitary stalk thickening (Figure 3).
case_images: MRI of sella turcica at 10-month follow-up (May 2015): normal pituitary size with discrete heterogenous enhancement.
case_images: CRIID2017-1489210.004.jpg
case_images: PMC5439250_01_CRIID2017-1489210.004.jpg
case_images: fig4
case_images: MRI of the sella turcica 10 months later showed an almost normal pituitary size with discrete heterogenous enhancement (Figure 4).